Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Ocugen ( (OCGN) ) is now available.
On June 22, 2025, Ocugen and its subsidiary OrthoCellix entered into a merger agreement with Carisma Therapeutics and its subsidiary. However, on September 16, 2025, Carisma terminated the merger due to Ocugen’s failure to secure $25 million in investments, attributed to poor market conditions and a tight Nasdaq compliance deadline. Ocugen plans to continue focusing on gene therapies and exploring alternatives beneficial for its shareholders.
The most recent analyst rating on (OCGN) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Ocugen stock, see the OCGN Stock Forecast page.
Spark’s Take on OCGN Stock
According to Spark, TipRanks’ AI Analyst, OCGN is a Neutral.
Ocugen’s stock score is primarily influenced by its strong technical momentum, despite significant financial challenges and valuation concerns. The earnings call provided positive clinical updates and strategic partnerships, but financial risks persist.
To see Spark’s full report on OCGN stock, click here.
More about Ocugen
Ocugen, Inc. operates in the biotechnology industry, focusing on gene therapies and regenerative cell therapy platforms. The company is involved in developing products like NeoCart® technology for treating knee articular cartilage defects.
Average Trading Volume: 4,220,728
Technical Sentiment Signal: Buy
Current Market Cap: $412.2M
For a thorough assessment of OCGN stock, go to TipRanks’ Stock Analysis page.